Aclaris Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis did not achieve its primary endpoint, while also announcing the initiation of a new Phase 2b trial and additional pipeline updates.

Key Highlights

  • Primary endpoint missed: The Phase 2 ADMIRATION trial did not achieve the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24, nor secondary endpoints.
  • Pharmacodynamic activity observed: According to the filing, PD results showed target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17.
  • Tolerability noted: The filing states bosakitug "was generally well tolerated in the trial."
  • ALPHA Trial initiated: Aclaris announced the start of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus.
  • ALPHA Trial top-line results expected: The company disclosed it expects top-line results from the oral erosive lichen planus cohort of the ALPHA Trial in the second half of 2027.
  • ATI-9494 IND filing planned: The registrant reported completing IND-enabling studies for ATI-9494 and expects to file the IND in the fourth quarter of 2026, with a Phase 1 trial initiation targeted for the first quarter of 2027.
  • ATI-052 Phase 2b planned: The registrant stated it intends to initiate a Phase 2b trial of ATI-052, its anti-TSLP/IL-4Ra bispecific antibody, in eosinophilic esophagitis in the first quarter of 2027.

Bosakitug ADMIRATION Trial Results and Pipeline Update from Aclaris Therapeutics

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) disclosed in an 8-K filed November 16, 2026, that its Phase 2 ADMIRATION trial of bosakitug (ATI-045), described in the filing as "a humanized anti-thymic stromal lymphopoietin monoclonal antibody," did not achieve the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24 in patients with moderate-to-severe atopic dermatitis. The filing also stated that secondary endpoints were not achieved. The registrant characterized bosakitug as "generally well tolerated" in the trial.

Despite the missed endpoints, the filing noted that pharmacodynamic results showed target engagement of TSLP and downregulation of biomarkers related to immune activation, including Th1, Th2, and Th17. These disclosures were made under Item 8.01 (Other Events) and Item 7.01 (Regulation FD Disclosure), with associated press releases furnished as Exhibits 99.1 and 99.2. The filing notes that information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Separately, the registrant announced the initiation of the ALPHA Trial, a randomized, double-blind, placebo-controlled Phase 2b study of modzatinib (ATI-2138), described as "an investigational oral inhibitor of interleukin-2-inducible T cell kinase and Janus kinase 3," in patients with moderate-to-severe lichen planus. Top-line results from the oral erosive lichen planus cohort are expected in the second half of 2027. The filing also disclosed that ATI-9494, the company's ITK/TXK inhibitor, has completed IND-enabling studies, with an IND filing expected in the fourth quarter of 2026 and Phase 1 trial initiation targeted for the first quarter of 2027. The filing contains forward-looking statements that the registrant identifies as subject to risks and uncertainties, including those described in its Annual Report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

Aclaris Therapeutics disclosed top-line results showing its Phase 2 bosakitug trial missed its primary and secondary endpoints, announced the launch of the ALPHA Trial for modzatinib, and provided pipeline milestones for ATI-9494 and ATI-052, all as of November 16, 2026.